Patients who develop signs and symptoms of CHF will be taken off treatment, but continued in the study for disease follow-up. They will receive treatment for CHF as prescribed by the HFSA (e.g., ACE inhibitors, angiotensin-II receptor blockers, β-blockers, diuretics, and cardiac glycosides, as needed; see Appendix D for HFSA guidelines). Consideration should be given to obtaining a cardiac consultation.